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Clinics and pathology 
Phenotype/cell stem origin 
The cell of origin is a peripheral CD4+ T-lymphocyte. 
The immunophenotype of the neoplastic clone is CD3+ 
CD5+ CD4+ CD25-. Rare CD8+/CD4- cases were 
observed. Clonality studies demonstrated a monoclonal 
rearrangement of the T-cell receptor (TCR). 
Epidemiology 
This is the most common form of cutaneous T-cell 
lymphoma. The annual incidence is around 0,3 cases 
per 100.000 in western countries. The median age at 
diagnosis is between 55 and 60 years, with a 2/1 male-
to-female ratio. 
Clinics 
The disease usually shows cutaneous patches, plaques, 
tumors or generalized erythroderma (Mycosis 
fungoides). Pruritus is a common symptom. 
Extracutaneous manifestations are more frequent in the 
presence of locally advanced disease (cutaneous 
tumors). The presence of erythroderma with circulating 
malignant cells (Sezary's cells) in the peripheral blood 
(PB) and in the bone marrow is consistent with Sezary's 
syndrome, which is usually associated with 
lymphadenopathy. Other sites of involvement in 
disseminated disease include the lungs, the 
gastrointestinal tract, the liver and the central nervous 
system. 
Pathology 
The tumor cell is a small lymphocyte with cerebriform 
nucleus, clumped chromatin and inconspicuous 
nucleoli. Epidermotropism by neoplastic CD4+ 
lymphocytes with the formation of  
Pautrier's microabsecsses is the hallmark of the dis ase. 
Treatment 
Phototherapy, radiation therapy and alpha interferon 
are the mainstay of treatment of cutaneous disease. 
Chemotherapy using various regimens was employed 
in cases displaying disseminated disease and in 
Sezary's syndrome with limited success. 
Prognosis 
The clinical stage is the most important indicator. 
Patient with limited cutaneous disease have an 
excellent prognosis. Patient with cutaneous tumours, 
generalized erythroderma, with Sezary's syndrome or 
extracutaneous disease usually have a short survival, 
ranging from 1 to 4 years. 
Cytogenetics 
Note 
The neoplastic cells have a low mitotic index and 
stimulation with phytohemagglutinin and interleuchin-2 
IL-2) and IL-7 were used. The probability of detecting 
an abnormal clone largely correlates with the clinial 
stage, being very low in those patents with limited 
disease. Chromosome aberrations are detectable by 
conventional cytogenetic analysis in up to 60% of the
cases with PB involvement (Sezary' syndrome). Two 
recurrent structural changes were identified, namely 
der(1)t(1;10)(p2;q2) and der(14)t(14;15)(q;q?). Other 
recurrent abnormalities include loss of chromosome 
material at 1p22 and 1p36, involvement of 
chromosome 10 and 17p. The involvement of regions 
containing the T-cell receptor subunits, were observed 
rarely. 
Cytogenetics molecular 
The absence of breaks involving the TCR regions was 
confirmed by fluorescence in situ hybridization. 
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Comparative genomic hybridization studies showed 
chromosome imbalances in 56% of the cases. DNA 
losses occurred at 1p (38%), 17p (21%), 10q (15%), 
and 19 (15%). DNA gains involved 4q (18%), 18 
(15%) and 17q (12%). 1p33-36 and 10q26 may 
represent regions of minimal recurrent deletion. On
chromosome 1p, two regions of minimal common 
deletion at 1p36 (D1S228 marker) and 1p22 (D1S2766 
marker) were defined by allelotyping. 
The microarray technology allowed for the 
identification of gains of distinct oncogene copy 
numbers in the majority of cases: RAF1 at 3p25; CTSB 
at 8p22; PAK1 at 11q13; and JUNB at 19p13. 
Amplification of the latter oncogene was found in some 
cases with strong nuclear expression of the 
corresponding protein product. 
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